Agios Pharma (AGIO) Tops Q2 EPS by 36c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/23/2026
- S&P, Nasdaq drop on tech selloff as concerns about hawkish Fed, AI spending mount
- Chip stocks plunge, but bargain-hunters stem losses in other tech names
- Oil prices steady as investors focus on Hormuz flows after peace talks
- South Korea leveraged ETF crisis sparks global chip selloff
- Trump announces nuclear deal with Iran, lifts Hormuz blockade
- Exclusive-China robot-hand-building unicorn Linkerbot targets $6 billion valuation
- Spain's ex-transport minister sentenced to 24 years for corruption
- China, US, UAE police arrest 276 telecom fraud suspects in Dubai
- Li Auto Inc. (LI) Breaks Ground on Chips R&D and Production Base
- 'Equal and opposite': BTIG's Krinsky sees sharp reversal ahead for chip stocks
Agios Pharma (AGIO) PT Raised to $89 at Needham & Company
August 2, 2018 11:51 AM EDTNeedham & Company raised its price target on Agios Pharma (NASDAQ: AGIO) to $89.00 (from $86.00) while maintaining a Buy rating.
Analyst Chad Messer commented, "Both TIBSOVO and IDHIFA are now approved in relapsed/refractory AML. Agios is focused on moving both drugs into earlier... More
